troglitazone has been researched along with Diathesis in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jin, M | 1 |
Saekusa, Y | 1 |
Dewa, Y | 1 |
Nishimura, J | 1 |
Matsumoto, S | 1 |
Shibutani, M | 1 |
Hasumi, K | 1 |
Mitsumori, K | 1 |
1 other study available for troglitazone and Diathesis
Article | Year |
---|---|
Hepatocarcinogenic susceptibility of rasH2 mice to troglitazone in a two-stage hepatocarcinogenesis model.
Topics: Animals; Biomarkers, Tumor; Body Weight; Carcinogens; Chromans; Disease Models, Animal; Disease Susc | 2009 |